Esmo Breast Cancer – Astra and Daiichi square up to Gilead
Datopotamab, a project with a very similar mechanism to Trodelvy, shows impressive early data in triple-negative breast cancer.
A surprise Keytruda approval, and what it means for biotech
A Her2-positive cancer is the setting for a Keytruda triplet that could influence the trial design of some immune-stimulating agents.
Biolinerx could mobilise interest in CXCR4 antagonism
A phase 3 win should remind investors about other clinical-stage CXCR4 antagonists.
Esker joins the Tyk2 race
The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.
